[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353539-105":59,"doc-detail-353539-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genome-wide-crispr-screen-identified-nek6-as-a-determinant-of-sensitivity-to-cdk46-inhibitor-in-endometrial-cancer","Genome-wide CRISPR screen identified NEK6 as a determinant of sensitivity to CDK4/6 inhibitor in endometrial cancer","","Genome-wide CRISPR-Cas9 knockout screening identifies NEK6 as an essential determinant of endometrial cancer cell vulnerability to CDK4/6 inhibitors. NEK6 levels control antitumor effects and act as a synthetic lethal target of CDK4/6 inhibition in EC. Dual inhibition of NEK6 and CDK4/6 markedly suppresses tumor growth in vitro and in vivo. Mechanistically, NEK6 binds YBX1 in the cytoplasm, promotes YBX1 Ser102 phosphorylation, drives nuclear translocation, and activates CDK2 and BCL2 transcription, supporting therapeutic synergy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genome-wide-crispr-screen-identified-nek6-as-a-determinant-of-sensitivity-to-cdk46-inhibitor-in-endometrial-cancer/353539/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genome-wide-crispr-screen-identified-nek6-as-a-determinant-of-sensitivity-to-cdk46-inhibitor-in-endometrial-cancer/353539.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main method used to discover drug-sensitivity determinants in this study?","Question",{"text":112,"@type":113},"The study used a genome-wide CRISPR-Cas9-based knockout screen to identify genes that modify the response to CDK4/6 inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does NEK6 influence the effectiveness of CDK4/6 inhibitors in endometrial cancer?",{"text":117,"@type":113},"NEK6 levels determine the anti-tumor effects of CDK4/6 inhibitors, and NEK6 was identified as a synthetic lethal target of these inhibitors in endometrial cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism explains the synergy between NEK6 and CDK4/6 inhibition?",{"text":121,"@type":113},"NEK6 binds YBX1 in the cytoplasm and facilitates phosphorylation at serine 102, promoting YBX1 nuclear translocation and activating CDK2 and BCL2 transcription.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353539,1790225541,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","TYPE Original Research PUBLISHED 05 January 2026  \nDOI 10.3389/fphar.2025.1725886  \nOPEN ACCESS  \nEDITED BY  \nDefang Li,  \nBinzhou Medical University, China  \nREVIEWED BY  \nJayaprakash N. Kolla,  \nInstitute of Molecular Genetics (ASCR), Czechia Li Lu,  \nCapital Medical University, China  \n*CORRESPONDENCE  \nChenmin Yang,  \n [ycm11185@rjh.com.cn](ycm11185@rjh.com.cn)[ ](ycm11185@rjh.com.cn)Weiwei Feng,  \n [wfeng7347@aliyun.com](wfeng7347@aliyun.com)  \nRECEIVED 15 October 2025  \nREVISED 02 December 2025  \nACCEPTED 04 December 2025  \nPUBLISHED 05 January 2026  \nCITATION  \nJian F, Zhu C, Wang Y, Zhou T, Yang C and Feng W (2026) Genome-wide CRISPR screen identiﬁed NEK6 as a determinant of sensitivity to CDK4/6 inhibitor in endometrial cancer.  \nFront. Pharmacol. 16:1725886 .  \ndoi: 10.3389/fphar.2025.1725886  \nCOPYRIGHT  \n© 2026 Jian, Zhu, Wang, Zhou, Yang and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nGenome-wide CRISPR screen identiﬁed NEK6 as a determinant of sensitivity to CDK4/6 inhibitor in endometrial cancer  \nFangfang Jian, Chongying Zhu, Yiwei Wang, Tianyu Zhou, Chenmin Yang* and Weiwei Feng*  \nDepartment of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China  \nEndometrial cancer (EC) harbors highly recurrent cell cycle pathway alterations, especially hyperactivation of the CCND1/CDK4/6 axis, raising the potential for use of CDK4/6 inhibitors in these cancers. In this study, we performed a genomewide CRISPR-Cas9-based knockout screen to identify genes that modify the response to CDK4/6 inhibitors. We found that NIMA-related kinase-6 (NEK6) levels determine the anti-tumor effects of CDK4/6 inhibitors and that NEK6 was a synthetic lethal target of CDK4/6 inhibitors in EC. We further demonstrated that combined inhibition of NEK6 and CDK4/6 resulted in marked suppression of tumor growth in vitro and in vivo. Mechanistically, NEK6 bound to Y-box binding protein-1 (YBX1) in the cytoplasm and facilitated its phosphorylation at serine 102 (p-YBX1S102), which promoted YBX1 nuclear translocation and further activated CDK2 and bcl2 transcription. As such, these data provided robust pre-clinical mechanistic evidence of synergy between NEK6 and CDK4/6 inhibitors and delineated a path for translation of these ﬁndings to preliminary clinical studies in EC patients.  \nKEYWORDS  \nCDK4/6 inhibitor, endometrial cancer, genome-wide CRISPR screen, NEK6, YBX1  \n1 Introduction  \nEndometrial cancer is the sixth most common cancer in women, with 417000 new diagnoses made globally in 2020 (Sung et al., 2021; Morice et al., 2016) . In the past several years, the incidence of EC has increased according to the age and size of the population (Sung et al., 2021), with 132% increase over the last 30 years. Unfortunately, survival outcomes of women with EC have not improved over the past decades, and the most recent trends indicate a rise in mortality rates of 1.8% per year since 2010 (How et al., 2024) . Immunotherapy has transformed the endometrial cancer treatment landscape, particularly for those exhibiting mismatch repair deﬁciency [MMRd/microsatellite instabilityhypermutated (MSI-H)] . However, outcomes for patients with advanced-stage and metastatic endometrial cancer remain unsatisfactory. Thus, there is an urgent need to identify and develop more effective therapeutic strategies to improve the prognosis of EC.  \nCell cycle is a series of tightly regulated molecular events that control cell division, and dysregulation of the cell cycle progression represents one of the hallmarks of tu","cbCailK8SY4CQmRF","https://ap.wps.com/l/cbCailK8SY4CQmRF","pdf",5738552,16,"English","# Introduction\n## Rationale for targeting the CCND1/CDK4/6 axis in endometrial cancer\n## Need for improved therapeutic strategies and relevance of cell-cycle dysregulation","[{\"question\":\"What was the main method used to discover drug-sensitivity determinants in this study?\",\"answer\":\"The study used a genome-wide CRISPR-Cas9-based knockout screen to identify genes that modify the response to CDK4/6 inhibitors.\"},{\"question\":\"How does NEK6 influence the effectiveness of CDK4/6 inhibitors in endometrial cancer?\",\"answer\":\"NEK6 levels determine the anti-tumor effects of CDK4/6 inhibitors, and NEK6 was identified as a synthetic lethal target of these inhibitors in endometrial cancer.\"},{\"question\":\"What mechanism explains the synergy between NEK6 and CDK4/6 inhibition?\",\"answer\":\"NEK6 binds YBX1 in the cytoplasm and facilitates phosphorylation at serine 102, promoting YBX1 nuclear translocation and activating CDK2 and BCL2 transcription.\"}]","Genome-wide CRISPR screen identified NEK6 as a determinant of sensitivity to CDK4/6 inhibitor in endometrial cancer | PDF",1790105965,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3ee78bb5b8a4fa4caafddb494597f2c.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7345e6cd635ab659a001e81f9d50817.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/274c6c902e64789b64bdbf53f217b6b5.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/983d9f9744ad978406664cb37d881f64.webp",980,1385]